vimarsana.com

Page 12 - இக்ஹ்ன் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

One of the original lab leak deniers calls for a thorough investigation into Covid s origin

EXCLUSIVE: Dr Peter Palese, a microbiologist i in New York, signed a letter claiming Covid could only have been natural in origin and to suggest otherwise creates fear, rumours, and prejudice .

iHealthScreen Inc meldet CE-Zertifizierung für automatisiertes KI-System iPredict zur Früherkennung von diabetischer Retinopathie (DR) und altersbedingter Makuladegeneration (AMD) sowie bei Verdacht auf Glaukom

iHealthScreen ist das erste Unternehmen in den Vereinigten Staaten, das eine CE-Zertifizierung für die gleichzeitige diagnostische Abklärung von DR, AMD und Glaukom-Verdachtsfällen erhält. Das iPredict

Kantaro s Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order

Share this article   - COVID-SeroKlir detects both the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity- -Available immediately and can be used in Canadian laboratories without proprietary equipment- NEW YORK, June 2, 2021 /PRNewswire/ Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENS /NASDAQ: RNLX), and its commercial partner Bio-Techne Corporation (NASDAQ: TECH), have received Health Canada Authorization under the COVID-19 Interim Order for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. COVID-SeroKlir measures the presence and precise level of spike protein IgG antibodies. These are neutralizing antibodies produced as part of the immune response to COVID-19 virus exposure or generated by a vaccine and may help prevent (re-)infection. The Mount Sinai Health System in New York City developed the test s underlying technology,

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer

A phase 3 clinical trial co-led by Mount Sinai researchers is the first to show that immunotherapy after surgery to remove bladder cancer can reduce the risk of relapse for patients who are at high risk of their cancer returning in a deadly metastatic form, according to results published in The New England Journal of Medicine. The immunotherapy nivolumab was used as an adjuvant therapy, which is given after surgery in the hopes of maximizing its effectiveness.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.